# testHP

## Biological Monitoring & Longevity Research Platform

`testHP` is a research-oriented project for building a **multimodal, longitudinal model of human biological state**. The long-term vision is to monitor the organism at multiple biological levels, detect abnormalities and ageing-related changes, understand how they evolve, and eventually evaluate interventions that preserve or restore biological function.

> **Vision:** treat the human body as a dynamic biological system rather than reducing health to one score or one diagnosis.

The long-term ambition includes research into exceptionally long healthy lifespans, potentially including a 200-year human lifespan. This is a research vision, not a current capability or medical claim.

---

## What problem is the project solving?

The system treats long-term health as two interacting problems:

1. **Ageing** — changes in cells, tissues, organs and biological systems over time.
2. **Pathology** — disease, infection, inflammation, cancer, injury and other abnormalities that can occur at any age.

Both should be monitored simultaneously.

```text
                         HUMAN ORGANISM
                                |
                +---------------+---------------+
                |                               |
             AGEING                          PATHOLOGY
                |                               |
        cellular changes                 disease processes
        tissue degeneration              inflammation
        molecular changes                infection
        functional decline               cancer
                |                               |
                +---------------+---------------+
                                |
                         BIOLOGICAL STATE
                                |
                     anomaly / risk / trend
                                |
                       next measurement
                                |
                         state is updated
```

---

## Multimodal monitoring

Different biological layers require different measurement technologies. The architecture therefore separates acquisition from interpretation.

Possible modalities include:

- MRI for structural measurements;
- microscopy for cellular and skin morphology;
- histopathology for tissue architecture;
- cell segmentation and single-cell analysis;
- RNA / transcriptomics;
- future proteomics and metabolomics;
- blood and laboratory measurements;
- physiological and wearable data;
- other specialised instruments as the project evolves.

```text
 MRI -----------+
 microscopy -----+
 histology ------+
 single-cell ----+----> modality-specific analysis
 RNA ------------+             |
 blood ----------+             v
 wearables ------+       biological features
                              |
                              v
                     multimodal integration
                              |
                              v
                      biological state
```

A new device should be addable without redesigning the whole system.

---

## Biological state instead of one health score

The project deliberately avoids reducing a person to a single value such as `biological_age = 52`.

Instead, the model is hierarchical:

```text
molecule -> cell -> tissue -> organ -> system -> organism
```

A state can contain organs, biomarkers, ageing scores and anomaly signals. Observations should also retain time, anatomy, modality, provenance, processing/model version and uncertainty where available.

The current implementation now has a whole-organism state model and longitudinal history, rather than isolated measurements.

---

## Current architecture

The repository has progressed through **15 development stages**. The implemented architecture currently includes:

```text
core/
    common biological data model

analysis/
    cell / tissue / morphology / pathology / RNA / ageing / anomaly / risk

segmentation/
    cell segmentation baseline

pipelines/
    cell analysis pipeline

organs/
    organ models and dependency graph
    signal propagation between organs

organism/
    whole-body state
    integrated health-state aggregation

longitudinal/
    trajectory and trend analysis

aging/
    biological clocks
    ageing profiles
    ageing trajectories

monitoring/
    longitudinal monitoring cycles
    anomaly -> risk -> investigation loop

tests/
    unit tests for the implemented components
```

The architecture is intentionally modular so that future imaging, omics and physiological models can plug into the same biological state representation.

---

## Development stages completed

### Stage 1 — Biological data core

Established common representations for subjects, timepoints, observations, measurements, biological states, biomarkers, anatomy and uncertainty.

### Stage 2 — First cell pipeline

Connected image/cell analysis to the common data model. The baseline pipeline can produce measurements such as cell count, density, area, compactness and spatial statistics.

### Stage 3 — Organ modelling

Introduced explicit organ-level state representation and organ dimensions.

### Stage 4 — Organ relationships

Added dependencies between organs, creating a graph representation of biological relationships.

### Stage 5 — Anomaly/risk foundation

Established the prototype mechanisms used to represent abnormal signals and aggregate risk-related information.

### Stage 6 — Tissue/organ integration

Connected lower-level biological observations with higher-level organ state.

### Stage 7 — Biological ageing foundation

Introduced ageing-related scoring and biological-clock concepts.

### Stage 8 — Intervention analysis foundation

Established a research representation for evaluating intervention-related observations and effects. It is not a treatment recommendation engine.

### Stage 9 — Risk/pathology integration

Added prototype analysis components for pathology, risk and abnormality interpretation.

### Stage 10 — Organ-level signal propagation

Added `organs/propagation.py` to propagate an observed signal through the organ dependency graph while retaining the propagation path.

### Stage 11 — Whole-body organism model

Added `organism/organism_model.py` with `OrganismState` and `OrganismModel`. The model stores longitudinal organism states and supports comparison of successive biomarker observations.

### Stage 12 — Integrated health state

Added `organism/health_state.py` with `HealthState` and `HealthStateAggregator`, combining organ signals and organism-level anomaly flags into a transparent whole-body summary.

### Stage 13 — Longitudinal trajectories

Added `longitudinal/trajectory.py` and the public trajectory API. The system can calculate direction, change and slope for repeated biological measurements.

### Stage 14 — Ageing trajectories

Added `aging/aging_trajectory.py` so individual biological ageing dimensions can be tracked over time and their rate of change estimated.

### Stage 15 — Continuous monitoring loop

Added the monitoring layer that stores repeated monitoring cycles containing organism state, anomalies, risk information and investigation/next-step information. This establishes the foundation for a closed-loop monitoring architecture.

```text
measurement
    ↓
quality / analysis
    ↓
biological state
    ↓
anomaly detection
    ↓
risk aggregation
    ↓
investigation / next measurement
    ↓
history
    ↓
trajectory + ageing analysis
    ↓
updated biological state
    ↓
repeat
```

---

## Biological ageing

Ageing should be represented by multiple dimensions rather than one universal clock.

Potential dimensions include:

```text
Cellular age
Tissue age
Immune age
Vascular age
Skeletal age
Neural age
Metabolic age
Molecular age
Functional age
```

The project now supports the conceptual transition from a single measurement to a trajectory:

```text
T0 ----> T1 ----> T2 ----> T3
 |        |        |        |
state    state    state    state
 |        |        |        |
 +--------+--------+--------+
             |
             v
        biological trend
```

For ageing research, **rate of change can be more informative than a single age estimate**. The current implementation provides transparent trend/slope primitives; it is not a clinically validated biological-age clock.

---

## Abnormality and disease detection

The intended system should detect both known and potentially unknown abnormalities:

- cellular abnormalities;
- tissue abnormalities;
- morphology changes;
- molecular abnormalities;
- pathology signals;
- longitudinal changes;
- disagreement between modalities;
- open-set or previously unseen patterns.

The system should be allowed to return **insufficient evidence** or **additional measurement required** instead of forcing an unjustified classification.

The current repository contains research prototypes and score aggregators, not clinically validated diagnostic models.

---

## Digital Biological Twin

A major long-term objective is a **Digital Biological Twin**: an evolving computational representation of an individual's biological state.

```text
                    DIGITAL BIOLOGICAL TWIN
                              |
       +----------------------+----------------------+
       |                      |                      |
     organs                 tissues                cells
       |                      |                      |
   function                morphology             state
       |                      |                      |
       +----------------------+----------------------+
                              |
                         molecular state
                              |
                        ageing trajectories
                              |
                         disease/risk state
                              |
                         interventions
                              |
                         uncertainty
```

The current `organism/`, `longitudinal/`, `aging/` and `monitoring/` layers are foundations for this future component. A complete digital twin is **not yet implemented**.

---

## Intervention and rejuvenation research

A long-term research objective is to monitor interventions intended to preserve or restore biological function.

Partial cellular reprogramming involving **Yamanaka factors** is one example of a research direction that illustrates why efficacy and safety must be monitored separately. Potential cellular rejuvenation effects must be evaluated alongside risks such as loss of cell identity, abnormal proliferation and tumour formation.

The intended architecture is:

```text
                    INTERVENTION
                         |
          +--------------+--------------+
          |              |              |
       efficacy        toxicity       safety
          |              |              |
          |        inflammation      genomic /
          |                         clonal changes
          |              |              |
          +--------------+--------------+
                         |
                    updated state
                         |
                  longitudinal follow-up
```

`testHP` does **not** currently implement or recommend a rejuvenation therapy. It is a research architecture for measuring biological state and, eventually, evaluating interventions under appropriate scientific and clinical validation.

---

## Safety and decision philosophy

The system is being designed around several safety principles:

1. **Observation is not diagnosis.**
2. **A risk score is not a medical decision.**
3. **Uncertainty must be represented rather than hidden.**
4. **Conflicting measurements should trigger investigation, not arbitrary averaging.**
5. **Potential treatment benefit must be monitored separately from toxicity and safety.**
6. **Automated outputs require appropriate human and clinical oversight before clinical use.**

The long-term decision layer should prefer actions such as **measure again**, **request another modality**, **review by an expert**, or **insufficient evidence** when uncertainty is high.

---

## Validation roadmap

Before any medical use, the project would need substantially more work:

```text
prototype
   ↓
unit / integration testing
   ↓
benchmark datasets
   ↓
external validation
   ↓
longitudinal cohorts
   ↓
prospective studies
   ↓
clinical validation
   ↓
regulatory / safety assessment
```

Performance must be evaluated separately for different modalities, populations, anatomical regions, diseases and measurement conditions. Reproducibility and data provenance are essential.

---

## Future roadmap — Stages 16+

The next development direction should be:

### Stage 16 — Unified multimodal observation layer

Create a single interface for MRI, microscopy, histology, omics, laboratory and wearable observations.

### Stage 17 — Measurement quality and uncertainty engine

Formalise quality control, missing data, confidence and conflicting measurements.

### Stage 18 — Multimodal fusion

Combine independent observations without destroying modality-specific provenance.

### Stage 19 — Hierarchical biological state

Connect molecule/cell/tissue/organ/system states into one navigable graph.

### Stage 20 — Digital Biological Twin foundation

Create the persistent evolving representation of an individual's biological state.

### Stage 21 — Advanced anomaly detection

Introduce open-set anomaly detection and cross-modality disagreement analysis.

### Stage 22 — Disease-versus-ageing modelling

Separate normal variation, ageing, pathology and measurement artefacts.

### Stage 23 — Intervention surveillance

Track efficacy and safety as separate longitudinal trajectories.

### Stage 24 — Validation framework

Build reproducible benchmarks, cohort evaluation and prospective validation infrastructure.

---

## Important limitations

`testHP` is currently a **research prototype**. It should not be used to diagnose disease, prescribe treatment, determine biological age for medical purposes, or make autonomous clinical decisions.

Many concepts in the architecture remain future goals. In particular, a complete multimodal fusion system, clinically validated ageing models, a complete digital biological twin, validated intervention monitoring and clinical decision support are **not yet implemented**.

The 200-year lifespan objective is a long-term research vision, not a demonstrated outcome of the software.

---

## Project status

**Current stage: Stage 15 — monitoring architecture implemented; early research prototype.**

Stages 1–15 establish the core path from biological observations to organism state, longitudinal trends, ageing trajectories and repeated monitoring cycles.

The immediate technical priorities are now reliability, integration and validation rather than simply adding more scoring models.

The intended direction is:

```text
measure
  -> validate quality
  -> analyse
  -> integrate
  -> understand state
  -> detect change
  -> estimate risk
  -> choose the next measurement
  -> update the model
  -> repeat
```

The ultimate goal is to build a platform that can continuously construct and update a **computational representation of human biological state**, enabling research into long-term health, ageing, disease prevention and biological rejuvenation.
